Instil Bio reports ongoing trials for AXN-2510/IMM2510 in NSCLC; financial results show cash reserves enabling operations beyond 2026. Instil Bio, Inc. announced ongoing enrollment for a clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results